Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
"Ideally, we want patients to lose adipose tissue and preserve their lean body mass
In the IMPACT trial, pemvidutide achieved mean weight losses of 4.8% and 5.8% with 1.2 and 1.8 mg doses respectively at 24 weeks, compared to 0.5% with placebo, with weight loss curves showing no evidence of plateauing, suggesting continued benefit with longer treatment [49-51]
[1] It is frequently used to treat ascites associated with cirrhosis and also has been used as a diagnostic aid for primary hyperaldosteronism
Injection therapy bypasses this limitation entirely, delivering pharmaceutical-grade glutathione directly into the bloodstream at full potency, where it is immediately available to the cells and tissues that need it most
Sarcopenia associated with chronic obstructive pulmonary disease
Week 21 onwards
